<DOC>
	<DOCNO>NCT02356419</DOCNO>
	<brief_summary>The study single center open test , dose successive incremental method take . In order determine tolerance safety single intravenous injection different dos rESP healthy subject , investigator trial . On hand , study preliminarily explore pharmacokinetics healthy subject .</brief_summary>
	<brief_title>rESP Medication With Single Intravenous Administration Dose Escalation Explore Tolerability , Safety Pharmacokinetic Characteristics</brief_title>
	<detailed_description>The study single center open test , dose successive incremental method take . The study include 4 group 0.5 ug/kg , 1.0ug/kg , 2.0ug/kg 3.0ug/kg , pharmacokinetic data ( screen period , administration , administration 15 , 30 , 60 minute , fourth , 8 , 12 , 24 , 36 , 48 , 72 hour , seventh , 10 , 14 , 21 , 28 day , 10 case group ) collect . In order determine tolerance safety single intravenous injection different dos rESP healthy subject , investigator trial . On hand , study preliminarily explore pharmacokinetics healthy subject .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Aged 1840 year old , male female 2 . Subjects previously healthy , whose physical examination normal 14 day ago screen examination 3 . The BMI 1925Kg/m2 ( BMI = weight / height2 ) 4 . Without anemia , white blood cell platelet count normal 5 . Heart , lung , liver kidney function normal 6 . Without smoke wine hobby 7 . Subjects voluntarily sign write informed consent . 1 . Allergic constitution previous history allergy biological product ; 2 . Pregnant lactating woman ; 3 . Female subject take oral contraceptive pill plan pregnancy clinical trial within 3 month administration ; male subject whose female partner plan pregnancy clinical trial within 3 month administration ; 4 . Female subject receive postmenopausal estrogen therapy ; 5 . With malignant hypertension hypertension poorly control previous history thromboembolic diseases disease hematopoietic system 6 . Abnormal liver function ( AST ALT 2 time great upper limit normal ) 7 . Hemoglobin great equal 160g/L ( male ) , 150 g/L ( female ) 8 . The percentage reticulocytes great equal 3 % 9 . Serum iron protein &lt; 20ng/ml 10 . Subjects donate blood 90 day enrol received blood transfusion therapy participate drug test 11. subject receive recombinant erythropoiesis stimulate protein rHuEPO 3 month enrol ; 12. recombinant erythropoiesis stimulate protein antibody ( RESP ) endogenous erythropoietin ( EPO ) antibody positive ; 13. drug know damage organ give 3 month enrol ; 14. subject whose HBsAg , HBeAg , antiHIV , antiHCV syphilis antibody positive ; 15. researcher believe factor suitable trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>